What to Expect From IDEXX Laboratories’ Next Quarterly Earnings Report?

Core Insights - IDEXX Laboratories, Inc. is a leading healthcare company focused on diagnostics for companion animals, livestock, and water quality, with a market cap of approximately $53.6 billion [1] Financial Performance - Analysts project IDEXX to report Q4 fiscal 2025 earnings of $2.93 per share, an increase of 11.8% from $2.62 in the same quarter last year [2] - For the fiscal year, expected EPS is $12.93, reflecting a 21.2% increase from $10.67 in fiscal 2024, with further growth anticipated to $14.42 in fiscal 2026 [3] Stock Performance - IDEXX shares have increased by 61.4% over the past 52 weeks, outperforming the S&P 500 Index's 16.9% return and the Health Care Select Sector SPDR Fund's 11.3% increase [4] Drivers of Growth - Strong financial results have boosted investor confidence, driven by robust performance in the Companion Animal Group Diagnostics segment and increased global instrument installations [5] - High demand for cloud-based software solutions and diagnostic products, along with effective strategic execution, has further supported share price gains [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for IDEXX, with eight out of 14 analysts recommending "Strong Buy," one suggesting "Moderate Buy," and five advising "Hold" [6] - The mean price target for IDEXX is $790.67, indicating an 18% potential upside from current levels [6]